Alpha 2.0
Login Register
» Authors » Lars Erik Kristensen

Lars Erik Kristensen

Explore the profile of Lars Erik Kristensen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 120
Citations 1508
Followers 0
Related Specialties
Rheumatology
General Medicine
Dermatology
Top 10 Co-Authors
Robin Christensen
Lene Dreyer
Henning Bliddal
Tanja Schjodt Jorgensen
Marie Skougaard
Marius Henriksen
Alexander Egeberg
Johan Askling
Lennart T H Jacobsson
Pil Hojgaard
Published In
Ann Rheum Dis
Rheumatology (Oxford)
J Rheumatol
BMJ Open
Arthritis Res Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Single-cell RNA sequencing highlights the influence of innate and adaptive immune response mechanisms in psoriatic arthritis
Nielsen M, Skougaard M, Drachmann C, Stisen Z, Ditlev S, Jessen L, et al.
Front Immunol . 2025 Mar; 15:1490051. PMID: 40084238
Introduction: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease displaying heterogeneous symptoms. However, the association between the clinical heterogeneity of PsA and disease immunopathogenesis remains poorly understood complicating diagnostic...
2.
Do cognitive bias and heuristics influence improvement in knee pain in patients with knee osteoarthritis treated with open label placebo? The CHIPS study - An exploratory study using questionnaire and group concept mapping
Annfeldt T, Ginnerup-Nielsen E, Waehrens E, Vase L, Kristensen L, Jorgensen T
Osteoarthr Cartil Open . 2025 Feb; 7(1):100574. PMID: 39975810
Objective: This study explored if the patient-experience and the affect heuristic influenced improvements in painful symptoms, in response to open label placebo injections in patients with knee OA. It furthermore...
3.
Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: Exploratory analyses of a randomized controlled trial
Poulsen A, Stisen Z, Skougaard M, Christensen R, Overgaard A, Gudbergsen H, et al.
Osteoarthr Cartil Open . 2025 Jan; 7(1):100562. PMID: 39877802
Objective: Obesity is a major risk factor for osteoarthritis (OA). Adipose tissues may be linked to OA development through secretion of potential proinflammatory cytokines including neutrophil gelatinase-associated lipocalin (NGAL). Our...
4.
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies
Kristensen L, Tillett W, Nash P, Coates L, Mease P, Ogdie A, et al.
Ther Adv Musculoskelet Dis . 2024 Nov; 16:1759720X241288071. PMID: 39534481
Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease that causes pain and fatigue, reduces physical function, and negatively impacts health-related quality of life (HRQoL). In the phase III BE...
5.
Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological study
Berg J, Nielsen S, Malm E, Ioannidis J, Furst D, Smolen J, et al.
Ann Rheum Dis . 2024 Nov; PMID: 39521451
Objective: To examine the association between study characteristics and the harms reported in randomised controlled trials (RCTs) on biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with inflammatory...
6.
Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study
Kristensen L, Ng K, Ngantcha M, Morel J, Lubrano E, Tillett W, et al.
RMD Open . 2024 Sep; 10(3). PMID: 39306343
Background: The psoriatic arthritis (PsA) Observational Study of Persistence of Treatment (PRO-SPIRIT) assesses effectiveness and persistence of real-world PsA treatments. Ixekizumab (IXE) is an interleukin (IL)-17A inhibitor (i) (IL-17Ai), approved...
7.
Predicting Psoriatic Arthritis in Psoriasis Patients - A Swiss Registry Study
Nielsen M, Petersen T, Maul L, Thyssen J, Thomsen S, Wu J, et al.
J Psoriasis Psoriatic Arthritis . 2024 Sep; 9(2):41-50. PMID: 39295895
Background: Psoriatic arthritis (PsA) is a prevalent comorbidity among patients with psoriasis, heavily contributing to their burden of disease, usually diagnosed several years after the diagnosis of psoriasis. Objectives: To...
8.
Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies
McInnes I, Mease P, Tanaka Y, Gossec L, Husni M, Kristensen L, et al.
ACR Open Rheumatol . 2024 Jul; 6(11):720-731. PMID: 39077886
Objective: The objective of this study was to assess 52-week efficacy and safety of bimekizumab in patients with active psoriatic arthritis (PsA) with or without concomitant methotrexate (+/-MTX) treatment at...
9.
The impact of an illness perception conversation on open-label placebo response in knee osteoarthritis: A randomised controlled trial
Ginnerup-Nielsen E, Jorgensen T, Dew-Hattens C, Christensen R, Berg J, Vase L, et al.
Osteoarthritis Cartilage . 2024 Jul; 32(12):1610-1619. PMID: 39029733
Objective: To compare the effect of an illness perception conversation (IPC), relative to a research participation conversation (RPC), on 2-week changes in knee pain in patients with knee osteoarthritis. Method:...
10.
Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data
Kristensen L, Deodhar A, Leung Y, Vranic I, Mortezavi M, Fallon L, et al.
Rheumatol Ther . 2024 May; 11(3):487-499. PMID: 38696034
In this commentary, we review clinical data which helps inform individualized benefit-risk assessment for tofacitinib in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS). ORAL Surveillance, a safety trial...